Serotonergic vulnerability and depression: assumptions, experimental evidence and implications
In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotone...
Gespeichert in:
Veröffentlicht in: | Molecular psychiatry 2007-06, Vol.12 (6), p.522-543 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 543 |
---|---|
container_issue | 6 |
container_start_page | 522 |
container_title | Molecular psychiatry |
container_volume | 12 |
creator | Jans, L A W Riedel, W J Markus, C R Blokland, A |
description | In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs. |
doi_str_mv | 10.1038/sj.mp.4001920 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_70538767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A188547030</galeid><sourcerecordid>A188547030</sourcerecordid><originalsourceid>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</originalsourceid><addsrcrecordid>eNqFktuL1TAQh4so7kUffVSKiz7ZY9LcfVsWb7Dgg_pqSNPpIYc2rUm7uP-9s3uqB8VFAsmQ-X5zSaYonlCyoYTp13m3GaYNJ4SamtwrjilXshJC6ftoM2EqTjU_Kk5y3iGDTvGwOKKKSkKkOi6-fYY0zmOEtA2-vFp6tFwT-jBfly62ZQtTgpzDGN-ULudlmGa086sSfkyQwgBxdn0JV6GF6OFWEoapD97dco-KB53rMzxez9Pi67u3Xy4-VJef3n-8OL-svNR8rnRDjWl05ziTrmmUIL4xrZDAfKuNVzX3hFPFNWWUSKEEk5q0XNcNow1nwE6Ll_u4Uxq_L5BnO4Tsoe9dhHHJVhHBtJLqvyA1UktuNIJnf4G7cUkRm7C15EJJ3CVSz--kakplbbg5hNq6HmyI3Tgn52_y2nOqteCKMILU5h8UrhaG4PGHuoD3fwiqvcCnMecEnZ3wQ1y6tpTYm9mweWeHya6zgfyztdalGaA90OswIPBiBVz2ru-Siz7kA4cPiPMjD5VmdMUtpEPTd2V-uhdENy8Jfkf85f8JN_HYww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>221162949</pqid></control><display><type>article</type><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</creator><creatorcontrib>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</creatorcontrib><description>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</description><identifier>ISSN: 1359-4184</identifier><identifier>EISSN: 1476-5578</identifier><identifier>DOI: 10.1038/sj.mp.4001920</identifier><identifier>PMID: 17160067</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Adult and adolescent clinical studies ; Animals ; Behavioral Sciences ; Biological and medical sciences ; Biological Psychology ; Depression ; Depression - metabolism ; Depressive Disorder - metabolism ; Drugs ; Emotional disorders ; Environment ; feature-review ; Female ; Genetic factors ; Humans ; Hypotheses ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Mental depression ; Metabolism ; Metabolites ; Models, Neurological ; Mood disorders ; Neurosciences ; Pathology ; Pharmacotherapy ; Psychiatry ; Psychology ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Serotonin ; Serotonin - deficiency ; Serotonin - metabolism ; Sex Factors ; Tryptophan</subject><ispartof>Molecular psychiatry, 2007-06, Vol.12 (6), p.522-543</ispartof><rights>Springer Nature Limited 2007</rights><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2007 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jun 2007</rights><rights>Nature Publishing Group 2007.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</citedby><cites>FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/sj.mp.4001920$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/sj.mp.4001920$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18764766$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17160067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jans, L A W</creatorcontrib><creatorcontrib>Riedel, W J</creatorcontrib><creatorcontrib>Markus, C R</creatorcontrib><creatorcontrib>Blokland, A</creatorcontrib><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><title>Molecular psychiatry</title><addtitle>Mol Psychiatry</addtitle><addtitle>Mol Psychiatry</addtitle><description>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</description><subject>Adult and adolescent clinical studies</subject><subject>Animals</subject><subject>Behavioral Sciences</subject><subject>Biological and medical sciences</subject><subject>Biological Psychology</subject><subject>Depression</subject><subject>Depression - metabolism</subject><subject>Depressive Disorder - metabolism</subject><subject>Drugs</subject><subject>Emotional disorders</subject><subject>Environment</subject><subject>feature-review</subject><subject>Female</subject><subject>Genetic factors</subject><subject>Humans</subject><subject>Hypotheses</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mental depression</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Models, Neurological</subject><subject>Mood disorders</subject><subject>Neurosciences</subject><subject>Pathology</subject><subject>Pharmacotherapy</subject><subject>Psychiatry</subject><subject>Psychology</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Serotonin</subject><subject>Serotonin - deficiency</subject><subject>Serotonin - metabolism</subject><subject>Sex Factors</subject><subject>Tryptophan</subject><issn>1359-4184</issn><issn>1476-5578</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFktuL1TAQh4so7kUffVSKiz7ZY9LcfVsWb7Dgg_pqSNPpIYc2rUm7uP-9s3uqB8VFAsmQ-X5zSaYonlCyoYTp13m3GaYNJ4SamtwrjilXshJC6ftoM2EqTjU_Kk5y3iGDTvGwOKKKSkKkOi6-fYY0zmOEtA2-vFp6tFwT-jBfly62ZQtTgpzDGN-ULudlmGa086sSfkyQwgBxdn0JV6GF6OFWEoapD97dco-KB53rMzxez9Pi67u3Xy4-VJef3n-8OL-svNR8rnRDjWl05ziTrmmUIL4xrZDAfKuNVzX3hFPFNWWUSKEEk5q0XNcNow1nwE6Ll_u4Uxq_L5BnO4Tsoe9dhHHJVhHBtJLqvyA1UktuNIJnf4G7cUkRm7C15EJJ3CVSz--kakplbbg5hNq6HmyI3Tgn52_y2nOqteCKMILU5h8UrhaG4PGHuoD3fwiqvcCnMecEnZ3wQ1y6tpTYm9mweWeHya6zgfyztdalGaA90OswIPBiBVz2ru-Siz7kA4cPiPMjD5VmdMUtpEPTd2V-uhdENy8Jfkf85f8JN_HYww</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Jans, L A W</creator><creator>Riedel, W J</creator><creator>Markus, C R</creator><creator>Blokland, A</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20070601</creationdate><title>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</title><author>Jans, L A W ; Riedel, W J ; Markus, C R ; Blokland, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c684t-8b199b8fa436abb750cb9d56e3cd89c724c041748131065753680d482b31b43e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult and adolescent clinical studies</topic><topic>Animals</topic><topic>Behavioral Sciences</topic><topic>Biological and medical sciences</topic><topic>Biological Psychology</topic><topic>Depression</topic><topic>Depression - metabolism</topic><topic>Depressive Disorder - metabolism</topic><topic>Drugs</topic><topic>Emotional disorders</topic><topic>Environment</topic><topic>feature-review</topic><topic>Female</topic><topic>Genetic factors</topic><topic>Humans</topic><topic>Hypotheses</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mental depression</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Models, Neurological</topic><topic>Mood disorders</topic><topic>Neurosciences</topic><topic>Pathology</topic><topic>Pharmacotherapy</topic><topic>Psychiatry</topic><topic>Psychology</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Serotonin</topic><topic>Serotonin - deficiency</topic><topic>Serotonin - metabolism</topic><topic>Sex Factors</topic><topic>Tryptophan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jans, L A W</creatorcontrib><creatorcontrib>Riedel, W J</creatorcontrib><creatorcontrib>Markus, C R</creatorcontrib><creatorcontrib>Blokland, A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular psychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jans, L A W</au><au>Riedel, W J</au><au>Markus, C R</au><au>Blokland, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serotonergic vulnerability and depression: assumptions, experimental evidence and implications</atitle><jtitle>Molecular psychiatry</jtitle><stitle>Mol Psychiatry</stitle><addtitle>Mol Psychiatry</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>12</volume><issue>6</issue><spage>522</spage><epage>543</epage><pages>522-543</pages><issn>1359-4184</issn><eissn>1476-5578</eissn><abstract>In recent years, the term serotonergic vulnerability (SV) has been used in scientific literature, but so far it has not been explicitly defined. This review article attempts to elucidate the SV concept. SV can be defined as increased sensitivity to natural or experimental alterations of the serotonergic (5-HTergic) system. Several factors that may disrupt the 5-HTergic system and hence contribute to SV are discussed, including genetic factors, female gender, personality characteristics, several types of stress and drug use. It is explained that SV can be demonstrated by means of manipulations of the 5-HTergic system, such as 5-HT challenges or acute tryptophan depletion (ATD). Results of 5-HT challenge studies and ATD studies are discussed in terms of their implications for the concept of SV. A model is proposed in which a combination of various factors that may compromise 5-HT functioning in one person can result in depression or other 5-HT-related pathology. By manipulating 5-HT levels, in particular with ATD, vulnerable subjects may be identified before pathology initiates, providing the opportunity to take preventive action. Although it is not likely that this model applies to all cases of depression, or is able to identify all vulnerable subjects, the strength of the model is that it may enable identification of vulnerable subjects before the 5-HT related pathology occurs.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>17160067</pmid><doi>10.1038/sj.mp.4001920</doi><tpages>22</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-4184 |
ispartof | Molecular psychiatry, 2007-06, Vol.12 (6), p.522-543 |
issn | 1359-4184 1476-5578 |
language | eng |
recordid | cdi_proquest_miscellaneous_70538767 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult and adolescent clinical studies Animals Behavioral Sciences Biological and medical sciences Biological Psychology Depression Depression - metabolism Depressive Disorder - metabolism Drugs Emotional disorders Environment feature-review Female Genetic factors Humans Hypotheses Male Medical sciences Medicine Medicine & Public Health Mental depression Metabolism Metabolites Models, Neurological Mood disorders Neurosciences Pathology Pharmacotherapy Psychiatry Psychology Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Serotonin Serotonin - deficiency Serotonin - metabolism Sex Factors Tryptophan |
title | Serotonergic vulnerability and depression: assumptions, experimental evidence and implications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A15%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serotonergic%20vulnerability%20and%20depression:%20assumptions,%20experimental%20evidence%20and%20implications&rft.jtitle=Molecular%20psychiatry&rft.au=Jans,%20L%20A%20W&rft.date=2007-06-01&rft.volume=12&rft.issue=6&rft.spage=522&rft.epage=543&rft.pages=522-543&rft.issn=1359-4184&rft.eissn=1476-5578&rft_id=info:doi/10.1038/sj.mp.4001920&rft_dat=%3Cgale_proqu%3EA188547030%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=221162949&rft_id=info:pmid/17160067&rft_galeid=A188547030&rfr_iscdi=true |